DANISH BIO – DANSK BIOTEK organizes four major plenary meetings for our members throughout the year to increase our members' knowledge regarding specific biotech topics and to facilitate networking. The events usually take place in February, May, September and November.

We also organize approximately four "saloon" meetings annually. They are small, intimate, "meet the expert" meetings with typically 6-20 participants advocating more in-depth discussion and knowledge-sharing on specific themes.

11 Oct 2022

Pila Pharma completes 13-week safety studies in rats with no adverse signals during the dosing phase

Malmö, October 11, 2022

PILA PHARMA AB (publ) (FN STO: PILA) today publishes that a 13-week oral safety study in rats has completed the in-life phase with no adverse signals during the dosing phase.

Outstanding investigations still to be completed include the pathology, and the bioanalysis and toxicokinetic analyses which are necessary to determine the safety margin for the coming 3-month clinical phase 2b study in diabetes. A pivotal 13-week study in “non-rodents” has now also been initiated. The in-life part of this 2nd part of the “13-week tox package” is due to be completed by the end of 2022 and all results of the “13-week safety package” are expected in early 2023.

Search DANISH BIO – DANSK BIOTEK

11 Oct 2022

Pila Pharma completes 13-week safety studies in rats with no adverse signals during the dosing phase